Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 2/2004

01-03-2004 | Case Report

Wegener's granulomatosis of the prostate gland

Authors: Ragnar Gunnarsson, Roald Omdal, Kjell H. Kjellevold, Christian L. Ellingsen

Published in: Rheumatology International | Issue 2/2004

Login to get access

Abstract

Wegener's granulomatosis (WG) is a systemic granulomatous vasculitis affecting medium and small arteries, venules, and arterioles. The upper and lower respiratory tract and kidney are primarily involved. Patients with classic WG essentially present with upper airway and pulmonary involvement. Renal disease is common. Involvement of other organ systems is also relatively frequent, most often heart, joints, muscles, eyes, skin, and central and/or peripheral nervous system. We present a patient in whom WG was diagnosed primarily because of prostate involvement. This seems to be a rare manifestation.
Literature
1.
Duna GF, Galperin C, Hoffman GS (1995) Wegener's granulomatosis. Rheum Dis Clin North Am 21:949–986PubMed
2.
Hoffman GS, Specks U (1998) Antineutrophil cytoplasmic antibodies. Arthritis Rheum 41:1521–1537PubMed
3.
Nolle B, Specks U, Ludemann J, Rohrbach MS, DeRemee RA, Gross WL (1989) Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann Intern Med 111:28–40PubMed
4.
Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, Lesavre P, Ludemann J, Rasmussen N, Sinico RA, Wiik A, van der Woude FJ (1998) Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR project for ANCA assay standardization. Kidney Int 53:743–753CrossRefPubMed
5.
Leavitt RY, Fauci AS, Bloch DA, Michel BA, Hunder GG, Arend WP, Calabrese LH, Fries JF, Lie JT, Lightfoot RW Jr (1990) The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 33:1101–1107PubMed
6.
Hoffman GS, Kerr GS, Leavitt RY, Hallahan CW, Lebovics RS, Travis WD, Rottem M, Fauci AS (1992) Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116:488–498PubMed
7.
Huong DL, Papo T, Piette JC, Wechsler B, Bletry O, Richard F, Valcke JC, Godeau P (1995) Urogenital manifestations of Wegener granulomatosis. Medicine (Baltimore) 74:152–161
8.
Murty GE, Powell PH (1991) Wegener's granulomatosis presenting as prostatitis. Br J Urol 67:107–108PubMed
9.
Adelizzi RA, Shockley FK, Pietras JR (1986) Wegener's granulomatosis with ureteric obstruction. J Rheumatol 13:448–451PubMed
10.
Fanger H, Hoffman M (1957) Wegener's granulomatosis: a case report. J Urol 77:78–81
11.
Middleton G, Karp D, Lee E, Cush J (1994) Wegener's granulomatosis presenting as lower back pain with prostatitis and ureteral obstruction. J Rheumatol 21:566–569PubMed
12.
Stillwell TJ, DeRemee RA, McDonald TJ, Weiland LH, Engen DE (1987) Prostatic involvement in Wegener's granulomatosis. J Urol 138:1251–1253PubMed
13.
Sozer IT (1986) Wegener's granulomatosis with infiltration of the prostate. Br J Urol 58:335
14.
Tung KT, Woolf A, Falzon M (1987) Prostatic involvement in Wegener's granulomatosis. Postgrad Med J 63:53–54
15.
Castleman B, McNeely BU (1965) Case records of the Massachusetts General Hospital. Case 41–1965. N Engl J Med 273:652–659PubMed
16.
Bray VJ, Hasbargen JA (1991) Prostatic involvement in Wegener's granulomatosis. Am J Kidney Dis 17:578–580PubMed
17.
Hussain SF, Baker JT, De Bolla AR (1990) Wegener's granulomatosis presenting as granulomatous prostatitis causing urinary retention. Br J Urol 65:104
18.
Yalowitz PA, Greene LF, Sheps SG, Carlin MR (1966) Wegener's granulomatosis involving the prostate gland: report of a case. J Urol 96:801–804PubMed
19.
Fienberg R (1953) Necrotizing granulomatosis and angiitis of the lungs with massive splenic necrosis and focal thrombotic granulomatous glomerulonephritis. Amer J Clin Path 23:413–428
20.
Friend DS (1963) Wegener's granulomatosis. A case report. Arch Intern Med 111:703–709
21.
Stillwell TJ, Engen DE, Farrow GM (1987) The clinical spectrum of granulomatous prostatitis: a report of 200 cases. J Urol 138:320–323PubMed
22.
Tanner FH, McDonald JR (1943) Granulomatous prostatitis: a histologic study of a group of granulomatous lesions collected from prostate glands. Arch Path 36:358
23.
Lamm DL, Stogdill VD, Stogdill BJ, Crispen RG (1986) Complications of bacillus Calmette-Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol 135:272–274PubMed
24.
Walton EW (1958) Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). BMJ 2:265–270
25.
Koldingsnes W, Nossent H (2000) Epidemiology of Wegener's granulomatosis in northern Norway. Arthritis Rheum 43:2481–2487CrossRefPubMed
Metadata
Title
Wegener's granulomatosis of the prostate gland
Authors
Ragnar Gunnarsson
Roald Omdal
Kjell H. Kjellevold
Christian L. Ellingsen
Publication date
01-03-2004
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 2/2004
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-003-0343-y

Other articles of this Issue 2/2004

Rheumatology International 2/2004 Go to the issue

Original Article

Human leukocyte antigen distribution in Israeli patients with psoriatic arthritis

Original Article

Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study

Original Article

Autoimmune reaction to type II collagen and cartilage degeneration in MRL/Mp-lpr/lpr mouse

Case Report

Bullous lupus erythematosus in a patient with pre-existing dermatomyositis

Original Article

Is female predominance in irritable bowel syndrome related to fibromyalgia?

Original Article

Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits